AFP and gastric cancer: In addition, according to the clinicopathological characteristics of patients, we found that activin B showed no statistically significant difference with respect to age, sex, N, M, AJCC stages and most tumor biomarkers (CEA, CA199, CA724 and AFP) of GC patients (Fig. S9A-I).